SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Ovarian Cancer Bio-
marker Research Act of 2007’’. 
SEC. 2. GRANTS FOR ESTABLISHMENT AND OPERATION OF 
RESEARCH CENTERS FOR THE STUDY OF 
OVARIAN CANCER BIOMARKERS. 
Subpart 1 of part C of the Public Health Service Act 
is amended by adding at the end the following new section: 
‘‘SEC. 417E. GRANTS FOR ESTABLISHMENT AND OPERATION 
OF RESEARCH CENTERS FOR THE STUDY OF 
OVARIAN CANCER BIOMARKERS. 
‘‘(a) IN GENERAL.—The Director of the Institute, in 
consultation with the directors of other relevant institutes 
and centers of the National Institutes of Health and the 
Department of Defense Ovarian Cancer Research Pro-
gram, shall enter into cooperative agreements with, or 
make grants to, public or nonprofit entities to establish 
and operate centers to conduct research on biomarkers for 
use in risk stratification for, and the early detection and 
screening of, ovarian cancer, including fallopian tube can-
cer or primary peritoneal cancer. Each center shall be 
known as an Ovarian Cancer Biomarker Center of Excel-
lence. 
‘‘(b) RESEARCH FUNDED.—Federal payments made 
under a cooperative agreement or grant under subsection 
(a) may be used for research on any of the following: 
VerDate Aug 31 2005 
21:33 Oct 01, 2007
Jkt 069200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H3689.IH
H3689
rwilkins on PROD1PC63 with BILLS
‘‘(1) The development and characterization of 
new biomarkers, and the refinement of existing bio-
markers, for ovarian cancer. 
‘‘(2) The clinical and laboratory validation of 
such biomarkers, including technical development, 
standardization of assay methods, sample prepara-
tion, reagents, reproducibility, portability, and other 
refinements. 
‘‘(3) The development and implementation of 
clinical and epidemiological research on the utiliza-
tion of biomarkers for the early detection and 
screening of ovarian cancer. 
‘‘(4) The development and implementation of 
repositories for new tissue, urine, serum, and other 
biological specimens (such as ascites and pleural 
fluids). 
‘‘(c) FIRST AGREEMENT OR GRANT.—Not later than 
1 year after the date of the enactment of this section, the 
Director of the Institute shall enter into the first coopera-
tive agreement or make the first grant under this section. 
‘‘(d) AVAILABILITY OF BANKED SPECIMENS.—The 
Director of the Institute shall make available for research 
conducted under this section banked serum and tissue 
specimens from clinical research regarding ovarian cancer 
VerDate Aug 31 2005 
21:33 Oct 01, 2007
Jkt 069200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\H3689.IH
H3689
rwilkins on PROD1PC63 with BILLS
that was funded by the Department of Health and Human 
Services. 
‘‘(e) REPORT.—Not later than the end of fiscal year 
2009, and annually thereafter, the Director of the Insti-
tute shall submit a report to the Congress on the coopera-
tive agreements entered into and the grants made under 
this section. 
‘‘(f) AUTHORIZATION OF APPROPRIATIONS.—For the 
purpose of carrying out this section, there are authorized 
to be appropriated $25,000,000 for each of the fiscal years 
2009 through 2012, and such sums as may be necessary 
for each of the fiscal years 2013 through 2019. Such au-
thorization of appropriations is in addition to any other 
authorization of appropriations that is available for such 
purpose.’’. 
SEC. 3. OVARIAN CANCER BIOMARKER CLINICAL TRIAL 
COMMITTEE. 
Subpart 1 of part C of the Public Health Service Act, 
as amended by section 2, is further amended by adding 
at the end the following new section: 
‘‘SEC. 417F. OVARIAN CANCER BIOMARKER CLINICAL TRIAL 
COMMITTEE. 
‘‘(a) OVARIAN CANCER BIOMARKER RESEARCH COM-
MITTEE ESTABLISHED.—The Director of the Institute 
shall establish an Ovarian Cancer Biomarker Clinical 
VerDate Aug 31 2005 
21:33 Oct 01, 2007
Jkt 069200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6201
E:\BILLS\H3689.IH
H3689
rwilkins on PROD1PC63 with BILLS
Trial Committee (in this section referred to as the ‘Com-
mittee’) to assist the Director to design and implement 
one or more national clinical trials, in accordance with this 
section, to determine the utility of using biomarkers vali-
dated pursuant to the research conducted under section 
417E for risk stratification for, and early detection and 
screening of, ovarian cancer. 
‘‘(b) MEMBERSHIP.— 
‘‘(1) NUMBER.—The Committee shall consist of 
11 voting members and such number of nonvoting 
members as the Director of the Institute determines 
appropriate. 
‘‘(2) APPOINTMENT.—The members of the 
Committee shall be appointed by the Director of the 
Institute, in consultation with appropriate national 
medical societies, research societies, and patient ad-
vocate organizations, as follows: 
‘‘(A) 
VOTING
MEMBERS.—The 
voting 
members of the Committee shall be appointed 
by the Director of the Institute as follows: 
‘‘(i) Two patient advocates. 
‘‘(ii) Two national experts in statis-
tical analysis, clinical trial design, and pa-
tient recruitment. 
VerDate Aug 31 2005 
21:33 Oct 01, 2007
Jkt 069200
PO 00000
Frm 00005
Fmt 6652
Sfmt 6201
E:\BILLS\H3689.IH
H3689
rwilkins on PROD1PC63 with BILLS
‘‘(iii) Two representatives from the 
Gynecologic Oncology Group. 
‘‘(iv) One representative from the De-
partment of Defense Ovarian Cancer Re-
search Program. 
‘‘(v) Four ovarian cancer researchers. 
‘‘(B) NONVOTING
MEMBERS.—The non-
voting members of the Committee shall include 
such individuals as the Director of the Institute 
determines to be appropriate. 
‘‘(3) PAY.—Members of the Committee shall 
serve without pay and those members who are full 
time officers or employees of the United States shall 
receive no additional pay by reason of their service 
on the Committee, except that members of the Com-
mittee shall receive travel expenses, including per 
diem in lieu of subsistence, in accordance with appli-
cable provisions under chapter I of chapter 57 of 
title 5, United States Code. 
‘‘(c) CHAIRPERSON.—The voting members of the 
Committee appointed under subsection (b)(2) shall select 
a chairperson from among such members. 
‘‘(d) MEETINGS.—The Committee shall meet at the 
call of the chairperson or upon the request of the Director 
of the Institute, but at least four times each year. 
VerDate Aug 31 2005 
21:33 Oct 01, 2007
Jkt 069200
PO 00000
Frm 00006
Fmt 6652
Sfmt 6201
E:\BILLS\H3689.IH
H3689
rwilkins on PROD1PC63 with BILLS